Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Phase 2

Completed

Conditions: Hematological Malignancies

Interventions: Biological: Pembrolizumab/vibostolimab coformuation

First Posted Date: 2021-08-13

Last Posted Date: 2024-12-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 191

Registration Number: NCT05005442

Locations: 🇧🇷
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0601), Natal, Rio Grande Do Norte, Brazil
🇺🇸
University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0021, Aurora, Colorado, United States
🇩🇰
Aarhus Universitetshospital, Skejby-Blodsygdomme ( Site 0362), Aarhus, Midtjylland, Denmark

and more 62 locations

A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)

Phase 1

Completed

Conditions: Moderate Hepatic Impairment

Interventions: Drug: Belzutifan

First Posted Date: 2021-08-09

Last Posted Date: 2025-01-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 17

Registration Number: NCT04995484

Locations: 🇺🇸
The Texas Liver Institute ( Site 0002), San Antonio, Texas, United States
🇺🇸
Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

Phase 1

Completed

Conditions: Renal Impairment
End Stage Renal Disease

Interventions: Drug: Belzutifan

First Posted Date: 2021-08-06

Last Posted Date: 2025-04-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 14

Registration Number: NCT04994522

Locations: 🇺🇸
Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Phase 2

Active, not recruiting

Conditions: PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

Interventions: Drug: Miransertib

First Posted Date: 2021-07-28

Last Posted Date: 2025-02-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 60

Registration Number: NCT04980872

Locations: 🇺🇸
Texas Children's Hospital ( Site 0104), Houston, Texas, United States
🇺🇸
Seattle Children's Hospital ( Site 0103), Seattle, Washington, United States
🇮🇹
Ospedale Pediatrico Bambino Gesù-Centro Trials ( Site 0087), Rome, Roma, Italy

and more 8 locations

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Phase 2

Active, not recruiting

Conditions: Neoplasm Malignant

Interventions: Drug: Pembrolizumab
Drug: Belzutifan
Drug: Lenvatinib

First Posted Date: 2021-07-26

Last Posted Date: 2025-04-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 730

Registration Number: NCT04976634

Locations: 🇺🇸
University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047), Tucson, Arizona, United States
🇺🇸
Brigitte Harris Cancer Pavilion ( Site 5055), Detroit, Michigan, United States
🇺🇸
Memorial Sloan Kettering Cancer Center ( Site 5050), New York, New York, United States

and more 54 locations

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Pembrolizumab SC
Biological: Pembrolizumab IV
Drug: Paclitaxel
Drug: Nab-Paclitaxel
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2021-07-09

Last Posted Date: 2024-12-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 531

Registration Number: NCT04956692

Locations: 🇫🇷
Institut Regional du Cancer de Montpellier - ICM ( Site 1003), Montpellier, Herault, France
🇺🇸
St. Bernards Medical Center ( Site 0103), Jonesboro, Arkansas, United States
🇺🇸
West Virginia University ( Site 0056), Morgantown, West Virginia, United States

and more 123 locations

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Phase 3

Active, not recruiting

Conditions: Metastatic Esophageal Squamous Cell Carcinoma

Interventions: Biological: Pembrolizumab
Drug: Lenvatinib
Drug: 5-FU
Drug: Oxaliplatin
Drug: Cisplatin
Drug: Paclitaxel
Drug: Leucovorin
Drug: Levoleucovorin

First Posted Date: 2021-07-02

Last Posted Date: 2025-03-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 862

Registration Number: NCT04949256

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center ( Site 0152), Baltimore, Maryland, United States
🇺🇸
UMASS Memorial Medical Center ( Site 0120), Worcester, Massachusetts, United States
🇯🇵
Kanagawa Cancer Center ( Site 9004), Yokohama, Kanagawa, Japan

and more 195 locations

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

Phase 2

Completed

Conditions: Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis

Interventions: Drug: Semaglutide 1.34 mg/mL
Drug: Efinopegdutide 20 mg/mL

First Posted Date: 2021-06-30

Last Posted Date: 2023-11-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 145

Registration Number: NCT04944992

Locations: 🇦🇷
CIPREC-Laboratorio ( Site 0104), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇮🇱
Carmel Hospital-Liver Unit ( Site 0705), Haifa, Israel
🇮🇱
Rabin Medical Center ( Site 0701), Petah-Tikva, Israel

and more 66 locations

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

Phase 3

Completed

Conditions: Coronavirus Disease (COVID-19)

Interventions: Drug: Placebo
Drug: Molnupiravir

First Posted Date: 2021-06-25

Last Posted Date: 2024-02-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 2441

Registration Number: NCT04939428

Locations: 🇺🇸
University of Missouri Hospital ( Site 2486), Columbia, Missouri, United States
🇺🇸
ECU Adult Specialty Care ( Site 2415), Greenville, North Carolina, United States
🇺🇸
ASCADA Research, LLC ( Site 2516), Fullerton, California, United States

and more 223 locations

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Phase 1

Recruiting

Conditions: Small Cell Lung Carcinoma

Interventions: Biological: coformulation pembrolizumab/quavonlimab
Biological: R-DXd
Biological: coformulation favezelimab/pembrolizumab
Drug: lenvatinib
Biological: MK-4830

First Posted Date: 2021-06-24

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 110

Registration Number: NCT04938817

Locations: 🇵🇱
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 3900), Warszawa, Mazowieckie, Poland
🇷🇺
N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( Site 3703), Saint Petersburg, Sankt-Peterburg, Russian Federation
🇺🇸
Banner MD Anderson Cancer Center ( Site 0152), Gilbert, Arizona, United States

and more 45 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy